ENGLEWOOD, Colo., Feb. 22, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, February 29, 2024 at 4:15 PM Eastern Time to discuss its financial results for the fourth quarter and full year ended December 31, 2023. Financial results will be issued in a press release prior to the call.
Zynex management will host the conference call, followed by a question and answer session.
Date: Thursday, February 29, 2024
Time: 4:15 PM Eastern Time (1:15 PM Pacific Time)
U.S. & Canada dial-in number: 800-836-8184
International number: 646-357-8785
Webcast: 4Q & Full Year 2024 Webcast Link
The Company will also provide a link at https://zynexmed.investorroom.com/ for those who wish to stream the call via webcast. Please call the conference telephone number 5-10 minutes prior to the start time.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.
Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+949 694 9594
Last Trade: | US$1.67 |
Daily Change: | 0.01 0.60 |
Daily Volume: | 17,756 |
Market Cap: | US$50.600M |
August 18, 2025 July 31, 2025 June 30, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load